Welcome!

News Feed Item

Tribute Pharmaceuticals Reports Full Year 2013 Results and Lays the Groundwork for Future Growth

MILTON, ONTARIO -- (Marketwired) -- 03/31/14 -- Tribute Pharmaceuticals Canada Inc. (OTCQB: TBUFF)(OTCBB: TBUFF)(PINKSHEETS: TBUFF) ("Tribute" or the "Company"), a Canadian specialty pharmaceutical company engaged in the acquisition, licensing, development and promotion of healthcare products in Canada and the United States, today announced financial results for its fiscal year ending December 31, 2013. In this press release, all dollar amounts are expressed in Canadian currency (unless otherwise noted) and results are reported in accordance with United States generally accepted accounting principles (U.S. GAAP).

Full Year 2013 Highlights:


--  Revenues increased 8.9% for the year ended December 31, 2013 compared to
    same period in 2012;

--  Gross profit was up 16% for the year ended December 31, 2013 compared to
    the same period in 2012;

--  The Investigational New Drug (IND) application for Bezalip(r) SR, a
    treatment for patients with severe hypertriglyceridemia, was cleared by
    the U.S. Food and Drug Administration (FDA);

--  Cambia(r), the only prescription non-steroidal anti-inflammatory drug
    available for the acute treatment of migraine was officially launched to
    primary care physicians in Canada;

--  IMS, an audited third party provider of sales data, reported a 36.3%
    increase in total prescriptions written for Cambia in Q4 2013 when
    compared to Q3 2013;

--  SWK Funding LLC and the Company entered into a credit agreement pursuant
    to which SWK Funding LLC advanced US$6,000,000;

--  The regulatory authorities of Hong Kong approved the sale of NeoVisc(r),
    a proprietary product developed by the Company used for the temporary
    replacement of synovial fluid in osteoarthritic joints.

"We continued to execute on our growth strategy in 2013 and set the foundation for continued growth in 2014," said Rob Harris, President and CEO of Tribute. "We made a significant investment in the primary care launch of Cambia early in 2013, including the expansion of our sales force. This expansion will further enable us to increase sales of all our promoted products in Canada, including Bezalip® SR, Soriatane® and NeoVisc®. Additionally, we now have the capacity to introduce new products in Canada utilizing our existing sales force, and our near term business development efforts are focused on this single goal. Overall, our combined objective in 2014 is to increase revenues through organic growth and through business development efforts, as well as to optimize operational performance."

Tribute also successfully filed an Investigational New Drug application with the US FDA for Bezalip® SR in 2013, and subsequently retained JSB-Partners, a global life sciences advisor, to take the lead on partnering discussions to find a U.S. co-development and commercial partner in the US

"Specific to our development efforts, we will continue to move Bezalip® SR forward in 2014 towards an eventual NDA filing in the U.S.," added Mr. Harris. "In parallel to our partnering discussions with Bezalip® SR, we will also look to exploit our proprietary products Uracyst® and NeoVisc® in new international territories. We expect an additional patent to be granted in Europe for Uracyst® this year, and we believe this will present new opportunities for the product and for the Company in this market. With our recent developments in mind, we look forward to the challenge of building on our successes, as we believe our achievements during the fiscal year ended December 31, 2013 laid the foundation for significant progress during 2014."

Wolfgang Stoiber of JSB Partners stated, "We are excited to be working with Tribute Pharmaceuticals on establishing a potential late stage development and future marketing partnership with another pharmaceutical company for their product Bezalip SR. Over the last 15 years we have helped numerous bio-pharmaceutical companies develop partnerships and joint ventures for their respected products and look forward to the possibility of completing a transaction on Bezalip SR".

Review of Full Year Operating Results

Total net revenues for the twelve-month period ended December 31, 2013 increased by 8.9% to $13,440,400 compared to $12,342,800 for the same period in 2012. The increase in sales between the corresponding periods was attributable to an increase in Licensed Domestic Product Net Sales of $275,400 or 3.3%; an increase in Other Domestic Product Sales of $872,000 or 35.0%; and $197,900 of Royalty and Licensing Revenue.

For the twelve month period ended December 31, 2013 gross profit was $5,997,300, higher by 16.0% or $828,400 compared to the prior year. Underlying improvements were due to additional gross profit of $347,800 from Licensed Domestic Product Net Sales, $303,300 from Other Domestic Product Sales and International Product Sales and $197,900 from Royalty and Licensing Revenues.

Selling, general and administrative expenses for the twelve-month period ended December 31, 2013 were $9,830,100 compared to $8,870,600 for the same period in 2012 for an increase of $959,500 or 10.8%. The increase in selling, general and administrative costs is primarily due to significant investment in the expansion of the Company's sales force for the launch of Cambia to primary care physicians in 2013, marketing expenses to grow its existing promoted products in Canada and an increase in regulatory costs related to the filing of the Bezalip SR IND with the FDA in the US.

Net loss for the twelve-month period ended December 31, 2013 was $6,572,400, compared to a net loss of $3,349,000 for the same period in 2012. This equates to a loss of ($0.13) per share compared to a loss of ($0.09) per share in 2012.

Excluding non-operating expenses for the twelve month period ended December 31, 2013 of $1,808,500; the net loss from operations was $5,078,700 as compared to the prior year net loss from operations of $4,420,700. The increase in the operational loss between these comparable periods represents higher selling, general and administrative costs and amortization of assets (non-cash) offset in part by increases in product margins.

On August 8, 2013, SWK Funding LLC ("SWK"), a wholly-owned subsidiary of SWK Holdings Corporation entered into a credit agreement (the "Credit Agreement") pursuant to which the lenders party thereto provided to Tribute a term loan in the principal amount of US$6,000,000 (the "Loan") which may be increased by an additional US$2,000,000 at the Company's request on or before December 31, 2014. In connection with this loan, Tribute exercised its rights under its loan and security agreement with MidCap to prepay the outstanding balance of the Company's term loan with MidCap. On February 4, 2014, pursuant to the terms of the Credit Agreement, SWK advanced the Company the remaining US$2,000,000 in available funds. All terms under the Credit Agreement apply to the additional loan.

The Company's cash and cash equivalents position amounted to $2,813,500 at December 31, 2013 compared to $2,283,900 at December 31, 2012.

About Tribute Pharmaceuticals Canada Inc.

Tribute is an emerging Canadian specialty pharmaceutical company engaged in the acquisition, licensing, development and management of pharmaceutical and healthcare products with its primary focus on the Canadian and US markets.

Tribute markets Cambia® (diclofenac potassium for oral solution), Bezalip® SR (bezafibrate), Soriatane® (acitretin), NeoVisc® (1.0% sodium hyaluronate solution) Uracyst® (sodium chondroitin sulfate solution 2%), and Collatamp G® (gentamicin-impregnated collagen) in the Canadian market. Additionally, the Company holds an exclusive license for Bezalip® SR in the US and its proprietary products NeoVisc® and Uracyst® are commercially available and are sold globally through various international partnerships.

For further information on Tribute visit the Company's website: http://www.tributepharma.com.

Tribute Pharmaceuticals' Forward-Looking Statement

This press release contains certain forward-looking statements about Tribute as defined in the Private Securities Litigation Reform Act of 1995, which statements can be identified by the use of forward-looking terminology, such as "may", "will", "expect", "intend", "anticipate", "estimate", "predict", "plan" or "continue" or the negative thereof or other variations thereon or comparable terminology referring to future events or results. Forward-looking statements, by their nature, are subject to risks and uncertainties, Tribute's actual results could differ materially from those anticipated in these forward-looking statements as a result of numerous factors, including statements regarding our expectations regarding clinical trials, the timing of clinical results, development timelines and regulatory filings and submissions for our product candidates, general economic conditions, the ability of Tribute to successfully integrate operations, and the timing of expenditures and expansion opportunities, any of which could cause actual results to vary materially from current results or anticipated future results. See Tribute's reports filed with the Canadian Securities Regulatory Authorities and the U.S. Securities and Exchange Commission from time to time for cautionary statements identifying important factors with respect to such forward-looking statements, including certain risks and uncertainties that could cause actual results to differ materially from results referred to in forward-looking statements. Tribute assumes no obligation to update the information contained in this press release to update forward-looking statements to reflect changed assumptions, the occurrence of anticipated events or changes in future operating results, financial condition or business over time.

Bezalip®SR and Soriatane® are registered trademarks and under license from Actavis Group PTC ehf Cambia® is a registered trademark and under license from Depomed, Inc.

Collatamp G® is a registered trademark and under license EUSA Pharma (Europe) Limited.

For further information on Tribute, visit http://www.tributepharma.com.


                     TRIBUTE PHARMACEUTICALS CANADA INC.
                   (formerly Stellar Pharmaceuticals Inc.)
                               BALANCE SHEETS

                      (Expressed in Canadian dollars)
                                                     As at            As at
                                              December 31,     December 31,
                                                      2013             2012
                                          ----------------- ----------------
                  ASSETS
Current
Cash and cash equivalents                   $    2,813,472    $   2,283,868
Accounts receivable, net of allowance of
 $nil (2012 - $nil)                                591,766        1,205,087
Inventories                                      1,044,831        1,000,557
Taxes recoverable                                  651,791          261,400
Loan receivable                                     15,814           15,814
Prepaid expenses and other receivables             165,886          118,910
Current portion of debt issuance costs,
 net                                                91,100          185,403
                                          ----------------- ----------------
  Total current assets                           5,374,660        5,071,039
Property, plant and equipment, net               1,089,919        1,159,375
Intangible assets, net                           9,717,173       10,883,179
Goodwill                                         3,599,077        3,599,077
Debt issuance costs, net                           253,712          115,862
                                          ----------------- ----------------
  Total assets                              $   20,034,541    $  20,828,532
                                          ----------------- ----------------
                                          ----------------- ----------------

                LIABILITIES
Current
Accounts payable and accrued liabilities    $    3,284,756    $   5,455,664
Current portion of long term debt                  204,700        1,305,840
Warrant liability                                2,966,714          202,213
Other current liability                             38,156                -
                                          ----------------- ----------------
  Total current liabilities                      6,494,326        6,963,717
Long term debt                                   5,640,102        1,815,791
Deferred tax liability                                   -          314,900
                                          ----------------- ----------------
  Total liabilities                             12,134,428        9,094,408
                                          ----------------- ----------------
                                          ----------------- ----------------

Contingencies and commitments

           SHAREHOLDERS' EQUITY
Capital Stock
AUTHORIZED
Unlimited - Non-voting convertible
 redeemable and retractable preferred
 shares with no par value
Unlimited - Common shares with no par
 value
ISSUED
  Common shares 51,081,238 (2012 -
   39,610,042)                                  19,947,290       17,589,957
Additional paid-in capital options               2,286,890        1,867,723
Accumulated other comprehensive loss               (38,156)               -
Deficit                                        (14,295,911)      (7,723,556)
                                          ----------------- ----------------
Total shareholders' equity                       7,900,113       11,734,124
                                          ----------------- ----------------
Total liabilities and shareholders' equity  $   20,034,541    $  20,828,532
                                          ----------------- ----------------
                                          ----------------- ----------------
                    TRIBUTE PHARMACEUTICALS CANADA INC.
                  (formerly Stellar Pharmaceuticals Inc.)
                        STATEMENTS OF OPERATIONS AND
                            COMPREHENSIVE (LOSS)
                      (Expressed in Canadian dollars)

                      For the Years Ended December 31,

                                                     2013              2012
                                         ----------------- -----------------
                                         ----------------- -----------------
Revenues
Licensed domestic product net sales        $    8,598,385    $    8,322,945
Other domestic product sales                    3,366,374         2,494,359
International product sales                     1,277,678         1,525,479
Royalty and licensing revenues                    197,924                 -
                                         ----------------- -----------------
Total revenues                                 13,440,361        12,342,783
                                         ----------------- -----------------
                                         ----------------- -----------------

Cost of sales
Licensor sales and distribution fees            5,844,494         5,916,845
Cost of products sold                           1,541,662         1,220,716
Write down of inventories                          56,935            36,345
                                         ----------------- -----------------
Total cost of sales                             7,443,091         7,173,906
                                         ----------------- -----------------
Gross Profit                                    5,997,270         5,168,877
                                         ----------------- -----------------

Expenses
Selling, general and administrative             9,830,132         8,870,609
Amortization                                    1,245,846           718,981
                                         ----------------- -----------------
Total operating expenses                       11,075,978         9,589,590
                                         ----------------- -----------------
                                         ----------------- -----------------
(Loss) from operations                         (5,078,708)       (4,420,713)

Non-operating income (expenses)
Change in warrant liability                      (399,217)          247,486
Cost of extending the warrant expiration                -          (135,157)
Change in fair value of contingent
 consideration                                          -            79,724
Research and development                                -           (21,402)
Loss on disposal of intangible asset             (161,200)                -
Loss on extinguishment of loan                   (620,835)                -
Accretion expense                                (103,775)         (140,154)
Interest expense                                 (527,079)         (253,143)
Interest income                                     3,559            13,940
                                         ----------------- -----------------
(Loss) and comprehensive (loss) before
 tax                                           (6,887,255)       (4,629,419)
Current income tax recovery                             -            71,153
Deferred income tax recovery                      314,900         1,209,300
                                         ----------------- -----------------
Net (loss) for the year                        (6,572,355)       (3,348,966)
                                         ----------------- -----------------
                                         ----------------- -----------------

Unrealized loss on derivative instrument,
 net of                                           (38,156)                -
                                         ----------------- -----------------
                                         ----------------- -----------------
Total comprehensive loss                   $   (6,610,511)   $   (3,348,966)
                                         ----------------- -----------------
                                         ----------------- -----------------

Loss Per Share
  - Basic                                  $        (0.13)   $        (0.09)
                                         ----------------- -----------------
                                         ----------------- -----------------
  - Diluted                                $        (0.13)   $        (0.09)
                                         ----------------- -----------------
                                         ----------------- -----------------
Weighted Average Number of Common
Shares Outstanding
  - Basic                                      49,169,414        39,167,419
                                         ----------------- -----------------
                                         ----------------- -----------------
  - Diluted                                    49,169,414        39,167,419
                                         ----------------- -----------------
                                         ----------------- -----------------
                    TRIBUTE PHARMACEUTICALS CANADA INC.
                  (formerly Stellar Pharmaceuticals Inc.)
                          STATEMENTS OF CASH FLOWS
                      (Expressed in Canadian dollars)

                      For the Years Ended December 31,


                                                     2013              2012
                                       ------------------- -----------------
                                       ------------------- -----------------
Cash flows from (used in) operating
 activities
Net (loss)                               $     (6,572,355)   $   (3,348,966)
Items not affecting cash:
 Deferred income tax recovery                    (314,900)       (1,209,300)
 Amortization                                   1,288,509           772,012
 Change in warrant liability                      399,217          (247,486)
 Cost of extending the warrant
  expiration                                            -           135,157
 Change in fair value of contingent
  consideration                                         -           (79,724)
 Stockbased compensation                          419,167           589,893
 Accretion expense                                103,775           140,154
 Loss on disposal of intangible asset             161,200                 -
 Loss of extinguishment of loan                   620,835                 -
 Change in non-cash operating assets
  and liabilities
                                               (1,643,044)        1,690,533
                                       ------------------- -----------------
Cash flows (used in) operating
 activities                                    (5,537,596)       (1,557,727)
                                       ------------------- -----------------

Cash flows (used in) investing
 activities
 Additions to property, plant and
  equipment                                       (26,795)          (49,272)
 Payment of contingent liabilities               (460,000)          (40,000)
 Increase in intangible assets                    (33,345)          (42,902)
 Increase in licensing agreements                       -          (750,000)
 Cash cost of acquisitions                              -          (425,000)
                                       ------------------- -----------------
Cash flows (used in) investing
 activities                                      (520,140)       (1,307,174)
                                       ------------------- -----------------

Cash flows from (used in) financing
 activities
 Financing costs deferred                        (305,227)         (341,489)
 Long term debt repayment                      (3,386,630)         (217,569)
 Long term debt issued                          6,084,437         3,500,000
 Units issued                                   4,713,787                 -
 Debt extinguishment costs                       (348,420)                -
 Share issuance costs                            (436,966)                -
                                       ------------------- -----------------
Cash flows from financing activities            6,320,981         2,940,942
                                       ------------------- -----------------

Changes in cash and cash equivalents              263,245            76,041
Change in cash due to changes in
 foreign exchange                                 266,359           (20,146)
Cash and cash equivalents, beginning of
 year                                           2,283,868         2,227,973
                                       ------------------- -----------------

Cash and cash equivalents, end of year   $      2,813,472    $    2,283,868
                                       ------------------- -----------------
                                       ------------------- -----------------

More Stories By Marketwired .

Copyright © 2009 Marketwired. All rights reserved. All the news releases provided by Marketwired are copyrighted. Any forms of copying other than an individual user's personal reference without express written permission is prohibited. Further distribution of these materials is strictly forbidden, including but not limited to, posting, emailing, faxing, archiving in a public database, redistributing via a computer network or in a printed form.

Latest Stories
The current age of digital transformation means that IT organizations must adapt their toolset to cover all digital experiences, beyond just the end users’. Today’s businesses can no longer focus solely on the digital interactions they manage with employees or customers; they must now contend with non-traditional factors. Whether it's the power of brand to make or break a company, the need to monitor across all locations 24/7, or the ability to proactively resolve issues, companies must adapt to...
"We focus on composable infrastructure. Composable infrastructure has been named by companies like Gartner as the evolution of the IT infrastructure where everything is now driven by software," explained Bruno Andrade, CEO and Founder of HTBase, in this SYS-CON.tv interview at 20th Cloud Expo, held June 6-8, 2017, at the Javits Center in New York City, NY.
"Tintri focuses on the Ops side of the DevOps, which basically is pushing more and more of the accessibility of the infrastructure to the developers and trying to get behind the scenes," explained Dhiraj Sehgal of Tintri in this SYS-CON.tv interview at 20th Cloud Expo, held June 6-8, 2017, at the Javits Center in New York City, NY.
Hardware virtualization and cloud computing allowed us to increase resource utilization and increase our flexibility to respond to business demand. Docker Containers are the next quantum leap - Are they?! Databases always represented an additional set of challenges unique to running workloads requiring a maximum of I/O, network, CPU resources combined with data locality.
For organizations that have amassed large sums of software complexity, taking a microservices approach is the first step toward DevOps and continuous improvement / development. Integrating system-level analysis with microservices makes it easier to change and add functionality to applications at any time without the increase of risk. Before you start big transformation projects or a cloud migration, make sure these changes won’t take down your entire organization.
Cloud promises the agility required by today’s digital businesses. As organizations adopt cloud based infrastructures and services, their IT resources become increasingly dynamic and hybrid in nature. Managing these require modern IT operations and tools. In his session at 20th Cloud Expo, Raj Sundaram, Senior Principal Product Manager at CA Technologies, will discuss how to modernize your IT operations in order to proactively manage your hybrid cloud and IT environments. He will be sharing bes...
Artificial intelligence, machine learning, neural networks. We’re in the midst of a wave of excitement around AI such as hasn’t been seen for a few decades. But those previous periods of inflated expectations led to troughs of disappointment. Will this time be different? Most likely. Applications of AI such as predictive analytics are already decreasing costs and improving reliability of industrial machinery. Furthermore, the funding and research going into AI now comes from a wide range of com...
In this presentation, Striim CTO and founder Steve Wilkes will discuss practical strategies for counteracting fraud and cyberattacks by leveraging real-time streaming analytics. In his session at @ThingsExpo, Steve Wilkes, Founder and Chief Technology Officer at Striim, will provide a detailed look into leveraging streaming data management to correlate events in real time, and identify potential breaches across IoT and non-IoT systems throughout the enterprise. Strategies for processing massive ...
SYS-CON Events announced today that GrapeUp, the leading provider of rapid product development at the speed of business, will exhibit at SYS-CON's 21st International Cloud Expo®, which will take place October 31-November 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA. Grape Up is a software company, specialized in cloud native application development and professional services related to Cloud Foundry PaaS. With five expert teams that operate in various sectors of the market acr...
Internet of @ThingsExpo, taking place October 31 - November 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA, is co-located with 21st Cloud Expo and will feature technical sessions from a rock star conference faculty and the leading industry players in the world. The Internet of Things (IoT) is the most profound change in personal and enterprise IT since the creation of the Worldwide Web more than 20 years ago. All major researchers estimate there will be tens of billions devic...
SYS-CON Events announced today that Ayehu will exhibit at SYS-CON's 21st International Cloud Expo®, which will take place on October 31 - November 2, 2017 at the Santa Clara Convention Center in Santa Clara California. Ayehu provides IT Process Automation & Orchestration solutions for IT and Security professionals to identify and resolve critical incidents and enable rapid containment, eradication, and recovery from cyber security breaches. Ayehu provides customers greater control over IT infras...
You know you need the cloud, but you’re hesitant to simply dump everything at Amazon since you know that not all workloads are suitable for cloud. You know that you want the kind of ease of use and scalability that you get with public cloud, but your applications are architected in a way that makes the public cloud a non-starter. You’re looking at private cloud solutions based on hyperconverged infrastructure, but you’re concerned with the limits inherent in those technologies.
SYS-CON Events announced today that MobiDev, a client-oriented software development company, will exhibit at SYS-CON's 21st International Cloud Expo®, which will take place October 31-November 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA. MobiDev is a software company that develops and delivers turn-key mobile apps, websites, web services, and complex software systems for startups and enterprises. Since 2009 it has grown from a small group of passionate engineers and business...
Today we can collect lots and lots of performance data. We build beautiful dashboards and even have fancy query languages to access and transform the data. Still performance data is a secret language only a couple of people understand. The more business becomes digital the more stakeholders are interested in this data including how it relates to business. Some of these people have never used a monitoring tool before. They have a question on their mind like “How is my application doing” but no id...
What's the role of an IT self-service portal when you get to continuous delivery and Infrastructure as Code? This general session showed how to create the continuous delivery culture and eight accelerators for leading the change. Don Demcsak is a DevOps and Cloud Native Modernization Principal for Dell EMC based out of New Jersey. He is a former, long time, Microsoft Most Valuable Professional, specializing in building and architecting Application Delivery Pipelines for hybrid legacy, and cloud ...